|1.||Rodrigo, Regina: 2 articles (01/2014 - 12/2007)|
|2.||Giorgi, M: 2 articles (09/2008 - 01/2001)|
|3.||Espadas, Isabel: 1 article (01/2015)|
|4.||Moratalla, Rosario: 1 article (01/2015)|
|5.||Del-Bel, Elaine A: 1 article (01/2015)|
|6.||Solís, Oscar: 1 article (01/2015)|
|7.||Piwnica-Worms, David: 1 article (07/2014)|
|8.||Ippolito, Joseph E: 1 article (07/2014)|
|9.||Collins, Lynne: 1 article (07/2014)|
|10.||Crowley, Jan: 1 article (07/2014)|
01/01/2012 - "Zaprinast dilated MCA from all groups but the response was diminished in MCA from piglets raised in hypoxia for 10 days. "
07/01/2000 - "Inhaled NO and zaprinast both decrease the pulmonary hypertensive response to hypoxia, and the combination abolishes the response. "
07/01/2000 - "The combination of zaprinast and inhaled NO (either before or during hypoxia) abolished the pulmonary hypertensive response to hypoxia. "
07/01/2000 - "Zaprinast alone decreased the pulmonary hypertensive response to hypoxia. "
01/01/1990 - "The cGMP-phosphodiesterase inhibitor M & B 22948, by itself, selectively reduced hypoxia-induced vasoconstriction, suggesting a modulating effect of endogenous cGMP during hypoxic vasoconstriction."
12/23/2005 - "These results suggest that zaprinast is effective against both acute pain and the facilitated pain state at the spinal level. "
12/23/2005 - "Zaprinast is a phosphodiesterase inhibitor that is active in various models of pain when administered locally. "
01/01/2006 - "Intrathecal zaprinast and morphine are effective against acute pain and facilitated pain state. "
06/01/2011 - "G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast."
|3.||Pulmonary Hypertension (Ayerza Syndrome)
02/01/2000 - "During pulmonary hypertension, lungs were studied with inhaled NO only, with infusion of zaprinast only (0.25 mg/kg bolus and 0.05 mg/kg/min infusion), and with a combination of the two. "
04/01/1995 - "Eight awake lambs with U-46619-induced pulmonary hypertension breathed three concentrations of NO (5, 10, and 20 ppm) in a random order before and during an intravenous Zaprinast infusion (0.1 mg.kg-1.min-1). "
01/01/2012 - "To determine whether the PDE5 inhibitor, zaprinast, causes dilation in pulmonary and middle cerebral arteries (MCA) of normoxic newborn piglets and those with chronic hypoxia-induced pulmonary hypertension, and to evaluate whether zaprinast alters responses to increased pressure (autoregulatory ability) of the MCA. "
02/01/1998 - "The present study was designed to examine the effects of inhaled nebulized zaprinast, alone, and combined with inhaled NO. Eight awake lambs with U46619-induced pulmonary hypertension sequentially breathed two concentrations of NO (5 and 20 ppm), followed by inhalation of aerosols generated from solutions containing four concentrations of zaprinast (10, 20, 30, and 50 mg/ml). "
01/01/2012 - "Pulmonary artery dilation to zaprinast supports the use of PDE5 inhibitors to treat pulmonary hypertension in neonates. "
09/01/2008 - "In addition, we examined the role of phosphodiesterase (PDE) and the rate of cAMP and cGMP degradation on the severity of levodopa-induced dyskinesias in animals pretreated with PDE inhibitor, zaprinast. "
09/01/2008 - "Pretreatment with zaprinast reduced the severity of levodopa-induced dyskinesias, and partly prevented the decrease in cyclic nucleotides compared with pretreatment with saline-levodopa. "
02/01/2011 - "Behavioural analysis of levodopa-induced abnormal involuntary movements was performed before and after the treatment with two different inhibitors of phosphodiesterases, zaprinast and UK-343664. "
01/01/2015 - "We also examined how increasing NO/cGMP signaling affects LID expression by acutely administering molsidomine (an NO donor) or zaprinast (a cGMP phosphodiesterase 5-PDE5 inhibitor) before l-DOPA in mice with established dyskinesia. "
|5.||Acute Kidney Injury (Acute Renal Failure)
06/01/1995 - "Zaprinast accelerates recovery from established acute renal failure in the rat."
06/01/1995 - "Therefore, the current investigation examined whether zaprinast (M&B 22948), a guanosine 3',5'-cyclic monophosphate (cGMP)-specific phosphodiesterase inhibitor, would be effective in the treatment of established acute renal failure in the rat. "
|3.||Guanylate Cyclase (Guanylyl Cyclase)
|6.||Methylene Blue (Methylthioninium Chloride)
|7.||Phosphodiesterase 5 Inhibitors
|8.||Levodopa (L Dopa)
|9.||Phosphoric Diester Hydrolases (Phosphodiesterases)
|3.||Surgical Instruments (Clip)